BRPI0409730A - tratamento da incontinência - Google Patents

tratamento da incontinência

Info

Publication number
BRPI0409730A
BRPI0409730A BRPI0409730-0A BRPI0409730A BRPI0409730A BR PI0409730 A BRPI0409730 A BR PI0409730A BR PI0409730 A BRPI0409730 A BR PI0409730A BR PI0409730 A BRPI0409730 A BR PI0409730A
Authority
BR
Brazil
Prior art keywords
incontinence
treatment
relates
treating
incontinence treatment
Prior art date
Application number
BRPI0409730-0A
Other languages
English (en)
Inventor
Gordon Mcmurray
Wesley Dennis Miner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33397006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0409730(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0409730A publication Critical patent/BRPI0409730A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TRATAMENTO DA INCONTINêNCIA". A invenção presente refere-se à utilização de agonistas de receptores 5-HT2C para o tratamento da incontinência urinária, de preferência a incontinência mista ou a incontinência urinária de estresse. A invenção também refere-se à utilização de antagonistas de receptores 5-HT2C para o tratamento da retenção de urina. A invenção presente Também refere-se a um método de tratamento da incontinência, a testes para despistar compostos úteis para o tratamento da incontinência, e a métodos para preparar composições para o tratamento da incontinência urinária.
BRPI0409730-0A 2003-04-25 2004-04-21 tratamento da incontinência BRPI0409730A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0309533 2003-04-25
PCT/IB2004/001437 WO2004096196A2 (en) 2003-04-25 2004-04-21 Treatment of incontinence with 5htc2 agonists

Publications (1)

Publication Number Publication Date
BRPI0409730A true BRPI0409730A (pt) 2006-05-09

Family

ID=33397006

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409730-0A BRPI0409730A (pt) 2003-04-25 2004-04-21 tratamento da incontinência

Country Status (13)

Country Link
EP (2) EP1620081A2 (pt)
JP (2) JP2006524679A (pt)
KR (3) KR20100103726A (pt)
CN (1) CN1780612B (pt)
AU (2) AU2004233745B2 (pt)
BR (1) BRPI0409730A (pt)
CA (2) CA2670067A1 (pt)
CL (1) CL2004000826A1 (pt)
MX (1) MXPA05011410A (pt)
MY (1) MY142857A (pt)
TW (1) TW200426142A (pt)
WO (1) WO2004096196A2 (pt)
ZA (1) ZA200507158B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
US20060258712A1 (en) * 2005-04-24 2006-11-16 Wyeth Methods for modulating bladder function
US20080234280A1 (en) * 2005-08-01 2008-09-25 Mcmurray Gordon Use of Mc4 Receptor Agonist Compounds
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
EP2039695A4 (en) 2006-07-11 2010-09-15 Takeda Pharmaceutical BICYCLIC HETEROCYLIC COMPOUND AND ITS USE
EP2123644B1 (en) 2007-03-07 2014-12-17 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
WO2009063993A1 (ja) * 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
WO2009063991A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited ピリドオキサゼピン誘導体およびその用途
EA021079B1 (ru) 2009-06-15 2015-03-31 Такеда Фармасьютикал Компани Лимитед Производные пиразинооксазепина
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
WO2012002583A1 (en) * 2010-07-02 2012-01-05 Vanderbilt University Method for treating schizophrenia and related diseases with a combination therapy
JP6198715B2 (ja) 2012-03-06 2017-09-20 武田薬品工業株式会社 三環性化合物
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
CA2044854A1 (en) 1990-07-19 1992-01-20 Hong-I Chen Method for preventing or treating urinary incontinence
EP0572863A1 (de) 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
TW270114B (pt) 1993-10-22 1996-02-11 Hoffmann La Roche
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria
WO1998030548A1 (en) 1997-01-13 1998-07-16 Yamanouchi Pharmaceutical Co., Ltd. 5-HT2c RECEPTOR AGONISTS AND AMINOALKYLINDAZOLE DERIVATIVES
WO1998033504A1 (en) 1997-02-03 1998-08-06 Akzo Nobel N.V. Treatment of urinary incontinence
ATE250573T1 (de) 1997-02-25 2003-10-15 Akzo Nobel Nv Azetidin- und pyrrolidinderivate
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU727654B2 (en) 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative
RU2198873C2 (ru) * 1998-02-26 2003-02-20 Акцо Нобель Н.В. Производные азетидина и пирролидина
AU4037699A (en) 1998-05-08 1999-11-29 Akzo Nobel N.V. Novel aryl-hydro naphthalenal kanamines
GB9819019D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819035D0 (en) 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819032D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds IV
GB9819020D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds III
GB9819033D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
GB9820767D0 (en) 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
AU1738900A (en) 1998-11-19 2000-06-05 Nortran Pharmaceuticals Inc. Serotonin ligands as pro-erectile compounds
NZ512765A (en) 1998-12-17 2003-10-31 Wyeth Corp 2,3,4,4A-tetrahydro-1H-pyrazino(1,2-A)quinoxalin- 5(6H)one derivatives being 5HT2C agonists
JP2002535396A (ja) 1999-01-27 2002-10-22 イーライ・リリー・アンド・カンパニー セロトニン（５−ｈｔ（２ｃ））アゴニストとしてのアミノアルキルベンゾフラン類
WO2000069437A1 (en) 1999-05-18 2000-11-23 Synaptic Pharmaceutical Corporation Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
WO2000076984A2 (en) * 1999-05-21 2000-12-21 Biovitrum Ab Novel compounds, their use and preparation
SE9901884D0 (sv) * 1999-05-21 1999-05-21 Pharmacia & Upjohn Ab Novel compounds their use and preparation
US6465467B1 (en) * 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
ATE277048T1 (de) 1999-06-15 2004-10-15 Bristol Myers Squibb Pharma Co Substituierte hetercyclisch kondensierte gamma carboline
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9918962D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
GB9918965D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
US20030004207A1 (en) 1999-11-29 2003-01-02 Douglas A. Craig Use of compounds which activate a 5-ht receptor to treat urinary incontinence
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
CA2402472A1 (en) 2000-03-14 2001-10-04 Michael Dalton Ennis 2,3,4,5-tetrahydro-1h-¬1,4|diazepino¬1,7a|indole compounds
AU5256301A (en) 2000-04-28 2001-11-12 Yamanouchi Pharmaceutical Co., Ltd. Froindazole derivative
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
NZ525699A (en) * 2000-11-20 2005-03-24 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor
CA2448729A1 (en) * 2000-11-20 2002-05-23 Biovitrum Ab Piperazinyl and piperidyl substituted heterocyclic compounds
US6498184B2 (en) * 2000-12-05 2002-12-24 Akzo Nobel N.V. Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
SK7042003A3 (en) 2000-12-20 2004-07-07 Bristol Myers Squibb Co Substituted pyridoindoles as serotonin agonists and antagonists
JP4386639B2 (ja) 2000-12-20 2009-12-16 ブリストル−マイヤーズ スクイブ カンパニー セロトニンアゴニストおよびアンタゴニストとしての置換されたピロロキノリン化合物およびピリドキノリン化合物
KR100539143B1 (ko) 2000-12-27 2005-12-26 에프. 호프만-라 로슈 아게 인돌 유도체 및 그의 5-ｈｔ2ｂ 및 5-ｈｔ2ｃ 수용체리간드로서의 용도
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
WO2002074746A1 (en) 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivatives
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
EP1404679A2 (en) 2001-07-05 2004-04-07 PHARMACIA & UPJOHN COMPANY (hetero)aryl substituted benzofurans as 5-ht ligands
MXPA04001202A (es) 2001-08-06 2005-02-17 Pharmacia & Upjhon Company Ligandos tetraciclicos terapeuticamente utiles.
CA2453537A1 (en) 2001-08-08 2003-02-20 Pharmacia & Upjohn Company Therapeutic 1h-pyrido¬4,3-b|indoles
BR0212676A (pt) 2001-09-21 2006-05-23 Upjohn Co compostos terapêuticos ligantes de 5-ht, composições farmacêuticas compreendendo tais compostos e seus usos
WO2003033497A1 (en) * 2001-10-18 2003-04-24 Pharmacia & Upjohn Company Tetracyclic azaindoles and -indolines having serotonin 5-ht2c activity
JP2005516964A (ja) 2001-12-28 2005-06-09 バイエル・フアーマシユーチカルズ・コーポレーシヨン ５−ｈｔ２ｃレセプターと関連する疾患における使用のための１ｈ−ピラゾリル誘導体化合物
AU2002367323A1 (en) 2001-12-28 2003-07-24 Bayer Pharmaceuticals Corporation Benzothieno (3,2-
AU2002360819A1 (en) 2001-12-28 2003-07-24 Bayer Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
EP1465872A1 (en) 2001-12-28 2004-10-13 Bayer Pharmaceuticals Corporation 4-sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
JP4460450B2 (ja) 2002-06-19 2010-05-12 ビオヴィトルム・アクチボラゲット（プブリクト） 新規化合物、その使用および製造法

Also Published As

Publication number Publication date
AU2004233745B2 (en) 2010-03-25
CL2004000826A1 (es) 2005-03-04
WO2004096196A2 (en) 2004-11-11
AU2010203093A1 (en) 2010-08-12
WO2004096196A3 (en) 2005-03-10
MY142857A (en) 2011-01-14
CA2523379C (en) 2010-06-22
KR20060006063A (ko) 2006-01-18
MXPA05011410A (es) 2005-12-12
KR20100103726A (ko) 2010-09-27
CN1780612B (zh) 2010-12-01
CN1780612A (zh) 2006-05-31
JP2006524679A (ja) 2006-11-02
JP2011064695A (ja) 2011-03-31
EP1620081A2 (en) 2006-02-01
CA2523379A1 (en) 2004-11-11
CA2670067A1 (en) 2004-11-11
KR20070108921A (ko) 2007-11-13
TW200426142A (en) 2004-12-01
ZA200507158B (en) 2006-11-29
EP2277513A2 (en) 2011-01-26
EP2277513A3 (en) 2011-09-07
AU2004233745A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
BRPI0409730A (pt) tratamento da incontinência
PT1199069E (pt) Utilização de um agonista/antagonista de estrogénio para melhoramento ou manutenção da saúde urogenital
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
BR0208179A (pt) Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto
BRPI0418092A (pt) combinação terapêutica para melhora cognitiva e transtornos psicóticos
BR0112631A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, pacote, métodos de reduzir a condutáncia de cálcio de um receptor de capsaicina e de tratar um mamìfero e uso de um composto
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
DE69728585D1 (de) Mittel gegen Juckreiz
BG108683A (en) Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
MY135333A (en) Modulators of the glucocorticoid receptor
NO20043013L (no) Tetrahydrokinolin analoger som muskarine agonister
BR0317229A (pt) Composição e uso de agonista completo de alfa7nachr
BG108427A (bg) 2,5-диарилпиразини, 2,5-диарилпиридини и 2,5-диарилпиримидини като модулатори на crf1 рецептори
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BR0308391A (pt) Derivados de pirazolo(1,5-a)piridina como moduladores neurotransmissores
UY26656A1 (es) "metabolitos agonistas/antagonistas de estrogeno"
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
DE60042446D1 (de) Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
WO2003072572A8 (en) Beta3-adrenergic receptor agonists
BR0206844A (pt) Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
BRPI0412268A (pt) compostos contendo um inibidor seletivo da recaptação de serotonina e antagonista de receptor 5-ht2a
BRPI0607669A2 (pt) agente para profilaxia e tratamento de pancreatite

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.